Synthesis and Leishmanicidal Activity of 1-[5-(5-Nitrofuran-2-yl)-1, 3, 4-Thiadiazole-2-yl]-4-BenzoylPiperazines

Alireza Foroumadi, Hadi Adibi, Sussan Kabudanian Ardestani, Samira Shirooie, Arezoo Bozorgomid and Ali Jafari

"Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran. 4Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran. 5Department of Biochemistry, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran. 6Student’s Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. 7Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

A series of (5-nitrofuran-2-yl)-1, 3, 4-thiadiazole-2-yl derivatives 6a–6e have been synthesized and screened for in-vitro anti-leishmanial activity against the promastigote form of L. major. The structure of Schiff bases were confirmed by 1H NMR, IR. Screening results indicate that all of the designed and synthesized final compounds (6a-6e) significantly reduced the viability of promastigotes of L. major in comparison to glucantime (IC_{50} 3× 10^3 μg/mL). Meta and Para substitutions in benzene ring containing compounds were more potent than other derivative and the most potent compounds were 6d, 6e with IC_{50} value 94 µm and 77.6 µm, respectively. The experimental data proposes that (5-nitrofuran-2-yl)-1, 3, 4-thiadiazole-2-yl derivatives may be further investigated as a candidate drug for treatment of cutaneous leishmaniasis.

Keywords: 1, 3, 4-Thiadiazole; Nitrofuran; Antileishmanial activity; Leishmania Major; Promastigote.

Introduction

Leishmaniasis is an infection caused by the protozoan parasites belonging to the genus Leishmania and transmitted by the bite of an infected Phlebotomus in the Old World and Lutzomyia in the New World (1).

This disease is still one of the world’s most neglected diseases, because is present in 98 countries some of which are among the poorest in the world. According to WHO data, 350 million people in 88 countries are considered at risk of contracting leishmaniasis, and some 2 million new cases occur annually (2). More than 90% of the CL cases occur in six countries, Iran, Afghanistan, Syria, Saudi Arabia, Brazil, and Peru (3, 4). In Iran, almost 20,000 people are infected with cutaneous leishmaniasis each year (5).

The present control measures depends on chemotherapy including pentavalent antimonial, miltefosine, paromomycin and amphotericin B as the standard drugs for treatment but these drugs are expensive and long-term administration (6). The drug resistance, severe toxic side effects to
this of drugs has been reported from many parts of the world (6, 7). Therefore there is an urgent need for an effective treatment for leishmaniasis that is safe, inexpensive, and orally available.

In the last decades, Heterocyclic ring systems find great importance in the medicinal chemistry research due to their interesting biological and synthetic applications. Among different heterocyclic compounds 1, 3, 4-thiadiazoles and their derivatives have gained importance. Thiadiazole is a 5-membered ring system containing hydrogen-binding domain, sulfur atom, and two-electron donor nitrogen system that exhibit broad spectrum of pharmacological properties such as: antibacterial (8-10), Antifungal (11), Anti-tubercular (12), Antiviral (13), Antioxidant (14), Antitumor (10,15), Anti-inflammatory (9) and etc. It is known that 1, 3, 4-thiadiazole ring are included in the structure of various drugs like Acetazolamide (16). Sulfathidole, Sulfamethizole, Cefadroxil, Cefazolin (17). Literature surveys demonstrated the promising anti-leishmaniasis activity of 1, 3, 4-thiadiazoles derivatives (18-20). Considering the biological significance of 1, 3, 4-thiadiazoles, we decided to synthesize some novel 1-[5-(5-nitrofuran-2-yl)-1, 3, 4-thiadiazole-2-yl]-4-benzoylepiperazines (6a-e) derivatives and screen them for antileishmaniasis activity.

**Chemistry**

All chemical and solvent used in this study were purchased from Merck AG Chemical and used without further purification. Melting points were determined on a Kofler hot stage apparatus and at room temperature. The IR spectra were obtained on a Shimadzu 470 spectrophotometer (potassium bromide disks).

\(^1\)H NMR spectra were recorded on a Varian unity 80 spectrometer and chemical shifts are reported in parts per million (d) relative to tetramethylsilane (TMS) as an internal standard. Merck silica gel 60 F254 plates were used for analytical TLC.

\[ 4.1.1.1\text{-benzoyl-4-}[5-(5-nitro-2-furyl)-1, 3, 4-thiadiazol-2-yl] \text{ piperazine (6a)} \]

Yeild 74%; mp 220-222 °C; IR (KBr) νmax: 1380 & 1510 (stretch NO\(_2\)), 1690 (stretch C=O), 3000-3200 (stretch CH, sp² aromatic), 1480 & 1500 (stretch C=C, aromatic), 2915 cm⁻¹ (stretch CH, sp³ aliphatic).

\[ \text{¹H-NMR (DMSO, 200MHZ); } δ (ppm): 7.94 (d, j=6, 2H, H\(_1\), H\(_6\) - phenyl), 7.64 (t, j=6, 2H, H\(_3\), H\(_5\) - phenyl), 7.51 (m, j=6, 3H, H\(_4\) - furan & H\(_4\) - phenyl), 3.84 -3.40 (m, 8H - piperazine). \]

\[ 4.1.2.1-(3-nitro benzoyl-4-[5-(5-nitro-2-furyl)-1, 3, 4-thiadiazol-2-yl] piperazine (6b). Yeild 96%; mp 198-200 °C; IR (KBr) vmax: 1350 & 1510 (stretch NO\(_2\)), 1690 (stretch C=O), 3000-3200 (stretch CH, sp² aromatic), 1480 & 1500 (stretch C=C, aromatic), 2915 cm⁻¹ (stretch CH, sp³ aliphatic). \]

\[ \text{¹H-NMR (DMSO, 200MHZ); } δ (ppm): 7.94 (d, j=6, 2H, H\(_1\), H\(_6\) - phenyl), 7.64 (t, j=6, 2H, H\(_3\), H\(_5\) - phenyl), 7.51 (m, j=6, 3H, H\(_4\) - furan & H\(_4\) - phenyl), 3.84 -3.40 (m, 8H - piperazine). \]

\[ 4.1.2.1-(3-nitro benzoyl-4-[5-(5-nitro-2-furyl)-1, 3, 4-thiadiazol-2-yl] piperazine (6b). Yeild 96%; mp 198-200 °C; IR (KBr) vmax: 1350 & 1510 (stretch NO\(_2\)), 1700 (stretch C=O), 3020-3200 (stretch CH, aromatic), 1440 & 1630 (stretch C=C, aromatic), 2950 cm⁻¹ (stretch CH, sp³ aliphatic). sp² \]

\[ \text{¹H-NMR (DMSO, 200 MHZ); } δ (ppm): 8.58 (s, 1H,H\(_2\) - phenyl), 8.42 (d, j=6, 1H, H\(_4\) - phenyl), 8.34 -3.40 (m, 8H - piperazine). \]
Scheme 1. Reagents and conditions: (i) thiosemicarbazide, EtOH, HCl, reflux, 1 h. (ii) NH₄Fe(SO₄)₂·12H₂O, H₂O, reflux, 16 h. (iii) NaNO₂, HCl, Cu, 0°C!rt, 3 h. (iv) piperazine, EtOH, reflux, 1 h. (v) benzoyl chloride, 3-nitro benzoyl chloride, 4-nitro benzoyl chloride, 4-methoxy benzoyl chloride, 4-methyl benzoyl chloride, pyridine, EtOH, rt, 24 h.

6a-e

6a: x=H, y=H
6b: x=H, y=NO₂
6c: x=NO₂, y=H
6d: x=OCH₃, y=H
6e: x=CH₃, y=H
8.33 (d, j=8, 1H, H₆-phenyl), 7.78 (t, j=8, 1H, H₅-phenyl), 7.39 (t, j=4, 2H, H₃, H₄-furan), 3.80-3.01 (m, 8H- piperazine).

4.1.3. 1-(4-nitro benzoyl-4-[5-(5-nitro-2-furyl)-1, 3, 4-thiadiazol-2-yl] piperazine (6c).
Yeild 80%; mp 213-215 °C; IR (KBr) νmax: 1350 & 1500 (stretch NO₂), 1680 (stretch C=O), 3000-3200 (stretch CH, aromatic), 1440 & 1610 (stretch C=C, aromatic), 2900cm⁻¹ (stretch CH, sp³ aliphatic).

¹H-NMR (DMSO, 200 MHZ); δ (ppm): 8.57 (d, j=6, 2H, H₃, H₄-furan), 8.31 (d, j=8, 2H, H₃, H₅-phenyl), 8.16 (d, j=8, 2H, H₃, H₅-phenyl), 3.75 (m, 8H- piperazine).

4.1.4. 1-(4-methoxy benzoyl-4-[5-(5-nitro-2-furyl)-1, 3, 4-thiadiazol-2-yl] piperazine (6d).
Yeild 74%; mp 212-214 °C; IR (KBr) νmax: 1350 & 1530 (stretch NO₂), 1690 (stretch C=O), 3000-3200 (stretch CH, sp² aromatic), 1430 & 1600 (stretch C=C, aromatic), 2900cm⁻¹ (stretch CH, sp³ aliphatic), 1160 & 1250cm⁻¹ (stretch C-O-methoxy).

¹H-NMR (DMSO, 200 MHZ); δ (ppm): 7.89 (d, j=7, 2H, H₃, H₄-furan), 7.44 (d, j=2, 2H, H₃, H₄-furan), 6.98 (d, j=7, 2H, H₃, H₄-phenyl), 3.81 (s, 3H- methoxy), 3.66- 3.36 (m, 8H-piperazine).

4.1.5. 1-(4-methyl benzoyl-4-[5-(5-nitro-2-furyl)-1, 3, 4-thiadiazol-2-yl] piperazine (6e).
Yeild 47%; mp 220-222 °C; IR (KBr) vmax: 1360 & 1520 (stretch NO₂), 1690 (stretch =O), 3050-3200 (stretch CH, sp² aromatic), 1440 & 1610 (stretch C=C, aromatic), 2900cm⁻¹ (stretch CH, sp³ aliphatic).

Parasite culture
The L. major strain MRHO/IR/75/ER was provided from Pasteur institute, Tehran (Iran). Promastigotes of L. major were cultured in-vitro at 26ºC in RPMI 1640 complete medium containing 10% FBS, 4 mm L-glutamine, 25 mm HEPES, 0.1 mm non-essential amino acid, 1 mm sodium pyruvate, 50 µm 2-ME, streptomycin (100 µg/mL), Penicillin (100 u/mL).

The parasites were collected from the logarithmic phase.

In-vitro evaluation of anti-promastigote activity
To determine the 50% inhibitory concentration (IC₅₀) against L.major, The synthesized compounds were dissolved in dimethyl sulphoxide (DMSO) ata concentration of 0.01% and diluted with RPMI medium. Promastigotes were counted in a Neubauerhemocytometer and seeded at 2.6× 10⁶ cells per well in 96-well plastic plates containing different concentrations of the compounds and RPMI 1640 complete medium, with a final volume of 200 µL. Cultured cells in the presence of DMSO were used as controls. The cultures were incubated for 24 hours at 26ºC, after which the growth of the parasites was assessed by counting the number of live promastigotes using a Neubauer hemocytometer. The IC₅₀ values were calculated using the formula IC₅₀ = X₀ - X / X₀ - X₀, where X₀ is the number of parasites in the control and X is the number of parasites in the treated sample.
viability controls, while glucantime were used as Leishmanicidal controls. After 24 h. incubation in 25°C, parasite viability was determined using the MTT assay (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide; thiazolyl-blue, Sigma, Germany). Assays were performed twice with three replicates per each concentration tested.

Statistical analysis

The results were defined as the mean values of at least three experiments. Statistical analysis was carried out by using the SPSS ver. 16 software.

Results and Discussion

For evaluation of anti-leishmanial properties of target compounds, the in-vitro activity was assessed against promastigote (log phase) forms of *L. major*. The inhibitory effects of compounds against promastigotes forms of *L. major* were measured after 72 h. following established procedures, at concentrations ranging from 25 to 100 μm. The IC₅₀ values registered after 24 h. of exposure are represented in Table 1 including Glucantime as the reference drug.

Our selection to synthesis and anti-leishmanial activity evaluation 1-[5-(5-nitrofuran-2-yl)-1,3,4-thiadiazole-2-yl]-4-benzoylepiperazines, in this paper was based on reports of the literature indicating that 5-(5-nitrofuran-2-yl)-1,3,4-thiadiazoles moiety has been effective against promastigote and amastigote forms *L. major* strain in-vivo and in-vitro (19, 20)

In the present work, all of the synthesized compounds (6a-e) were more effective than the reference drug. The activity is increased in the following order: 6e > 6d > 6b > 6c > 6a. Compound 6e was found to be the most active compound in this series (IC₅₀ = 77.6 μm). (Screening results indicate that Meta and Para substitutions in benzene ring increase the efficacy and decrease IC₅₀ of the synthesis compounds and compounds with electron donor groups (as in compounds 6e, 6d) have greater activity than the others.

Conclusion

In summary, a series of 1-[5-(5-nitrofuran-2-yl)-1,3,4-thiadiazole-2-yl]-4-benzoylepiperazines were synthesized and evaluated for their in-vitro inhibitory activity against the *Leishmania* parasite. All of the target compounds exhibited good anti-leishmanial activity against the promastigote form of *L. major*. These data encourage furthermore studies evaluating the effect on intracellular amastigotes in-vitro, in-vivo efficacy and cytotoxicity of the compounds.

Acknowledgement

We gratefully acknowledge Vice Chancellery for Research and Technology, Kermanshah University of Medical Sciences for financial support (Grant No. 88020). This work was performed in partial fulfillment of the requirements for Pharm. D. of Samira Shirooie in Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran. The authors declare that there is no conflict of interests.

References

(1) Nagill R and Kaur S. Vaccine candidates for leishmaniasis: a review. *Int. Immunopharmacol.* (2011) 11: 1464-88.
(2) (http://www.who.int/ neglected_diseases/integrated_media_leishmaniasis/en/index.html)
(3) Ashford R and Desjeux P. Estimation of population at risk of infection and number of cases of leishmaniasis. *Parasitol. Today* (1992) 8: 104-5.
(4) Hamzavi Y and Khademi N. Trend of Cutaneous Leishmaniasis in Kermanshah Province, West of Iran from 1990 To 2012. *Iran. J. Parasitol.* (2015) 10:78.
(5) Mohebali M. Visceral leishmaniasis in Iran: review of the epidemiological and clinical features. *Iran. J. Parasitol.* (2013) 8: 348.
(6) Kedzierski L, Zhu Y and Handman E. Leishmania vaccines: progress and problems. *Parasitology* (2006) 133: S87-S112.
(7) Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A and Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant *Leishmania tropica* parasites. *PLoS. Med.* (2006) 3: e162.
(8) Abdel-Wahab BF, Abdel-Aziz HA and Ahmed EM. Synthesis and antimicrobial evaluation of some 1, 3-thiazole, 1, 2, 4-triazole derivatives including a 5-(benzofuran-2-yl)-1-phenylpyrazole moiety. *Monatsh. Chem.* (2009) 140: 601-5.
(9) Kadi AA, Al-Abdullah ES, Shehata IA, Habib EE, Ibrahim TM and El-Emam AA. Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1, 3, 4-thiadiazole derivatives. *Eur. J. Med. Chem.* (2010) 45: 5006-11.

(10) Foroumadi A, Sorkhi M, Moshaﬁ MH, Safavi M, Rineh A, Siavoshi F, Shafiee A and Emami S. 2-Substituted-5-nitroheterocycles: *In-vitro* anti-Helicobacter pylori activity and structure-activity relationship study. *Med. Chem.* (2009) 5: 529-34.

(11) Matysiak J and Malinski Z. 2-(2, 4-dihydroxyphenyl)-1, 3, 4-thiadiazole analogues: Antifungal activity *in-vitro* against Candida species. *Russ. J. Bioorg. Chem.* (2007) 33: 594-601.

(12) Foroumadi A, Asadipour A, Mirzaei M, Karimi J and Emami S. Antituberculosis agents. V. Synthesis, evaluation of *in-vitro* antituberculosis activity and cytotoxicity of some 2-(5-nitro-2-furyl)-1, 3, 4-thiadiazole derivatives. *Il Farmaco.* (2002) 57: 765-9.

(13) Invidiata F, Simoni D, Scintu F and Pinna N. 3, 6-Disubstituted 1, 2, 4-triazolo [3, 4-b][1, 3, 4] thiadiazoles: synthesis, antimicrobial and antiviral activity. *Il Farmaco* (Societa chimica italiana: 1989) (1996) 51: 659-4.

(14) Khan I, Ali S, Hameed S, Rama NH, Hussain MT, Wadood A, Uddin R, Ul-Haq Z, Khan A, Ali S and Choudhary M. Synthesis, antioxidant activities and urease inhibition of some new 1, 2, 4-triazole and 1, 3, 4-thiadiazole derivatives. *Eur. J. Med. Chem.* (2010) 45: 5200-7.

(15) Wei M-X, Feng L, Li X-Q, Zhou X-Z and Shao ZH. Synthesis of new chiral 2, 5-disubstituted 1, 3, 4-thiadiazoles possessing γ-butenolide moiety and preliminary evaluation of *in-vitro* anticancer activity. *Eur J. Med. Chem.* (2009) 44: 3340-4.

(16) Tsuji K and Ishikawa H. Synthesis and anti-pseudomonal activity of new 2-isocephems with a dihydroxypyridone moiety at C-7. *Bioorg. Med. Chem. Lett.* (1994) 4: 1601-6.

(17) Ferrer S, Borrás J, Miratvilles C and Fuertes A. Coordination behavior of acetazolamide (5-acetamido-1, 3, 4-thiadiazole-2-sulfonamide) F synthesis, crystal structure, and properties of bis (acetazolamidato) tetraamminenickel (II). *Inorg. Chem.* (1989) 28: 160-3.

(18) Behrouzi-Fardmoghdam M, Poorrajab F, Ardestani SK, Emami S, Shafiee A and Foroumadi A. Synthesis and *in-vitro* anti-leishmanial activity of 1-[5-(5-nitrofuran-2-yl)-1, 3, 4-thiadiazol-2-y1]-1-[5-(5-nitrothiophen-2-yl)-1, 3, 4-thiadiazol-2-yl]-4-arylpirperazines. *Bioorg. Med. Chem.* (2008) 16: 4509-15.

(19) Poorrajab F, Ardestani SK, Foroumadi A, Emami S, Kariminta A, Behrouzi-Fardmoghdam M, Shafiee A. Selective leishmanicidal effect of 1, 3, 4-thiadiazole derivatives and possible mechanism of action against Leishmania species. * Exp. Parasitol.* (2009) 121: 323-30.

(20) Tahghighi A, Marznaki FR, Kobarfard F, Dastmalchi S, Mozarrad JS, Razmi S, Ardestani SK, Emami S, Shafiee A and Foroumadi A. Synthesis and antileishmanial activity of novel 5-(5-nitrofuran-2-yl)-1, 3, 4-thiadiazoles with piperazinyl-linked benzamide substituents. *Eur. J. Med. Chem.* (2011) 46: 2602-8.

This article is available online at http://www.ijpr.ir